Detalhe da pesquisa
1.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 403(10434): 1341-1350, 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38521086
2.
Survival with Cemiplimab in Recurrent Cervical Cancer.
N Engl J Med
; 386(6): 544-555, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139273
3.
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
Oncologist
; 29(1): 25-35, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37523661
4.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
N Engl J Med
; 385(20): 1856-1867, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534429
5.
Radiological characteristics of skeletal growth in neonates and infants with achondroplasia.
Am J Med Genet A
; 194(5): e63525, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38158382
6.
Clinical outcomes and medical management of achondroplasia in Japanese children: A retrospective medical record review of clinical data.
Am J Med Genet A
; : e63612, 2024 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38554024
7.
What can cause cancer patients to attempt suicide? Thiamine deficiency mimicking the symptoms of major depressive disorder.
Palliat Support Care
; 22(1): 205-208, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37496388
8.
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(4): 392-402, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36878237
9.
NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer.
Future Oncol
; 19(25): 1715-1727, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37650734
10.
Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study.
Cancer Sci
; 113(8): 2788-2797, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35633184
11.
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775.
Cancer Sci
; 113(10): 3489-3497, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35612971
12.
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Cancer Sci
; 113(11): 3877-3887, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35792064
13.
Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma.
BMC Cancer
; 22(1): 59, 2022 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35027024
14.
Association between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancer.
BMC Cancer
; 22(1): 437, 2022 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35449092
15.
A novel pathogenic variant p.Asp797Val in IFIH1 in a Japanese boy with overlapping Singleton-Merten syndrome and Aicardi-Goutières syndrome.
Am J Med Genet A
; 188(1): 249-252, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34453469
16.
Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
Gynecol Oncol
; 165(1): 82-89, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35216808
17.
A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma.
J Pathol
; 255(3): 285-295, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34322886
18.
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Int J Gynecol Cancer
; 32(1): 93-100, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34799418
19.
Identification of a Novel Oncogenic Fusion Gene SPON1-TRIM29 in Clinical Ovarian Cancer That Promotes Cell and Tumor Growth and Enhances Chemoresistance in A2780 Cells.
Int J Mol Sci
; 23(2)2022 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35054873
20.
Opioid withdrawal syndrome developing after long-term administration of naldemedine.
Palliat Support Care
; 20(6): 897-899, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35543119